The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Trabectedin: A Review of its Use in the Management of Soft Tissue Sarcoma and Ovarian Cancer
Abstract
Trabectedin (Yondelis); ET-743) is an antineoplastic agent that was originally derived from the Caribbean marine tunicate Ecteinascidia turbinata and is now produced synthetically. It binds to the minor groove of DNA, disrupting the cell cycle and inhibiting cell proliferation. Intravenous trabectedin administered once every 3 weeks is approved as monotherapy in Europe for use in patients with advanced soft tissue sarcoma (STS) after failure of standard therapy with anthracyclines or ifosfamide, or who are unsuited to receive these agents. It also has orphan drug status in STS in the US and in ovarian cancer in the US and Europe, and is under investigation as combination therapy in patients with recurrent ovarian cancer. In clinical trials, trabectedin showed efficacy in the treatment of patients with advanced or metastatic STS, especially those with leiomyosarcoma or liposarcoma, as well as in women with platinum-sensitive advanced or recurrent ovarian cancer. In addition, its tolerability profile was generally manageable. The introduction of trabectedin expands the currently limited range of effective treatment options for patients with advanced or metastatic STS; trabectedin also has the potential to be a beneficial treatment for advanced or recurrent ovarian cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It was claimed to block the substantial DNA and transcription interacting effect as the chemical structure binds to the minor groove of DNA covalently and interact with transcription factors (e.g., SP-1) directly [223].”
From Marine Natural Products: A Source of Novel Anticancer Drugs (2019) · cites this paper as [223]
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B. N., Wenzel, L. B., Huang, H. Q., Baergen, R. N., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,626
Parmar, M., Ledermann, J. A., Colombo, N., du Bois, A., Jf, D., Kristensen, G. B., Wheeler, S., Swart, A. M., Qian, W., Torri, V., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13718-x · Cited by 1,180
Soft-Tissue Sarcomas in Adults
Clark, M. A., Fisher, C., Judson, I. R., & Thomas, J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041866 · Cited by 910
Cormier, J. N., & Pollock, R. E. (2004) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.54.2.94 · Cited by 861
Marine natural products as anticancer drugs
Simmons, T. L., Andrianasolo, E., McPhail, K., Flatt, P., & Gerwick, W. H. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.333.4.2 · Cited by 597
Grosso, F., Jones, R. L., Demetri, G. D., Judson, I. R., Blay, J., Cesne, A. L., Sanfilippo, R. G., Casieri, P., Collini, P., Dileo, P., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70175-4 · Cited by 490
Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas
Glabbeke, M. M. V., Verweij, J., Judson, I. R., & Nielsen, O. S. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00398-7 · Cited by 462
Cesne, A. L., Blay, J., Judson, I. R., van Oosterom, A., Verweij, J., Radford, J. A., Lorigan, P. C., Rodenhuis, S., Ray-Coquard, I., Bonvalot, S., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.180 · Cited by 458
Research works printed but not linked: 8
- Aletti, 2007, Mayo Clin Proc, 82, 751, 10.1016/S0025-6196(11)61196-8 · DOI
- Friedman, 2002, Cancer Res, 62, 3377
- Scotlandi, 2002, Clin Cancer Res, 8, 3893
- Li, 2001, Clin Cancer Res, 7, 2908
- Takahashi, 2001, Clin Cancer Res, 7, 3251
- Manara, 2005, Int J Oncol, 27, 1605
- Donald, 2003, Cancer Res, 63, 5902
- van Kesteren, 2000, Clin Cancer Res, 6, 4725
Cited by
Sorted by citations
Natural products to drugs: natural product-derived compounds in clinical trials
Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,086
Natural compounds for cancer treatment and prevention
Nobili, S., Lippi, D., Witort, E., Donnini, M., Bausi, L., Mini, E., & Capaccioli, S. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.01.017 · Cited by 780
Lordan, S., Ross, R. P., & Stanton, C. (2011) · Marine Drugs · doi:10.3390/md9061056 · Cited by 779
Marine Natural Products: A Source of Novel Anticancer Drugs
Khalifa, S. A. M., Elias, N., Farag, M. A., Chen, L., Saeed, A., Hegazy, M.-E. F., Moustafa, M. S., Abd El-Wahed, A., Al-Mousawi, S. M., Musharraf, S. G., et al. (2019) · Marine Drugs · doi:10.3390/md17090491 · Cited by 555
Demetri, G. D., Chawla, S. P., von Mehren, M., Ritch, P. S., Baker, L. H., Blay, J., Hande, K. R., Keohan, M. L., Samuels, B. L., Schuetze, S. M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.0088 · Cited by 537
Marine Bioactive Compounds and Their Health Benefits: A Review
Hamed, I., Özogul, F., Özogul, Y., & Regenstein, J. M. (2015) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.12136 · Cited by 444
Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer
Monk, B. J., Herzog, T. J., Kaye, S. B., Krasner, C. N., Vermorken, J. B., Muggia, F. M., Pujade-Lauraine, E., Lisyanskaya, A. S., Makhson, A. N., Rolski, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4037 · Cited by 395
Wu, Q., Qian, W., Sun, X., & Jiang, S. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01362-9 · Cited by 208
Villa, F. A., & Gerwick, L. G. (2010) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923970903296136 · Cited by 160
Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives
Mabuchi, S., Sugiyama, T., & Kimura, T. (2016) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2016.27.e31 · Cited by 153
Gronchi, A., Bui, B., Bonvalot, S., Pilotti, S., Ferrari, S., Hohenberger, P., Hohl, R. J., Demetri, G. D., Cesne, A. L., Lardelli, P., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr265 · Cited by 149
Ready for a comeback of natural products in oncology
Bailly, C. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.12.013 · Cited by 120
DNA minor groove binders: Back in the groove
Cai, X., Gray, P. J., & Hoff, D. D. V. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.02.004 · Cited by 116
A phase 2 study of temsirolimus (CCI‐779) in patients with soft tissue sarcomas
Okuno, S. H., Bailey, H. H., Mahoney, M. R., Adkins, D. R., Maples, W. J., Fitch, T. R., Ettinger, D. S., Erlichman, C., & Sarkaria, J. N. (2011) · Cancer · doi:10.1002/cncr.25928 · Cited by 83
Drug-induced hepatotoxicity in cancer patients - implication for treatment
Vincenzi, B., Armento, G., Ceruso, M. S., Catania, G., Leakos, M., Santini, D., Minotti, G., & Tonini, G. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1194824 · Cited by 81
Cesne, A. L., Yovine, A. J., Blay, J., Delaloge, S., Maki, R. G., Misset, J. L., Frontelo, P., Nieto, A., Jiao, J. J., & Demetri, G. D. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9662-0 · Cited by 78
Carter, N. J., & Keam, S. J. (2010) · Drugs · doi:10.2165/11202860-000000000-00000 · Cited by 74
Self-citationRole of chemotherapy in the management of soft tissue sarcomas
Krikelis, D., & Judson, I. R. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.176 · Cited by 72
Marine Natural Products with P-Glycoprotein Inhibitor Properties
Lopéz, D., & Martínez‐Luis, S. (2014) · Marine Drugs · doi:10.3390/md12010525 · Cited by 74
Current Status on Marine Products with Reversal Effect on Cancer Multidrug Resistance
Abraham, I., Sayed, K. A. E., Chen, Z., & Guo, H. (2012) · Marine Drugs · doi:10.3390/md10102312 · Cited by 68
del Campo, J. M., Roszak, A., Bidziński, M., Ciuleanu, T., Högberg, T., Wojtukiewicz, M. Z., Poveda, A. M., Boman, K., Westermann, A. M., & Lebedinsky, C. A. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp198 · Cited by 65
Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies
Mantia-Smaldone, Edwards, & Vlad, A. (2010) · Cancer Management and Research · doi:10.2147/cmar.s8759 · Cited by 63
Kaye, S. B., Colombo, N., Monk, B. J., Tjulandin, S., Kong, B., Roy, M., Chan, S. Y. T., Filipczyk−Cisarż, E., Hagberg, H., Vergote, I. B., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq353 · Cited by 60
Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma
Schöffski, P., Dumez, H., Wolter, P., Stefan, C., Woźniak, A., Jimeno, J. M., & van Oosterom, A. T. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.9.1609 · Cited by 58
Tadesse, M., Gulliksen, B., Strøm, M. B., Styrvold, O. B., & Haug, T. (2008) · Journal of Invertebrate Pathology · doi:10.1016/j.jip.2008.06.009 · Cited by 52
The Role of Macrophage/B-Cell Interactions in the Pathophysiology of B-Cell Lymphomas
Pham, L. V., Pogue, E., & Ford, R. J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00147 · Cited by 49
Biosynthesis of 3-Hydroxy-5-Methyl-O-Methyltyrosine in the Saframycin/Safracin Biosynthetic Pathway
Fu, C.-Y. (2008) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.0808.484 · Cited by 45
Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma
Sanctis, R. D., Marrari, A., Marchetti, S., Mussi, C., Balzarini, L., Lutman, R. F., Daolio, P. A., Bastoni, S., Bertuzzi, A. F., Quagliuolo, V., et al. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s92395 · Cited by 41
Natural Products in Drug Discovery: Impacts and Opportunities — An Assessment
Brahmachari, G. (2011) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789814335386_0001 · Cited by 45
Dahlem, C., Siow, W. X., Lopatniuk, M., Tse, W. K. F., Kessler, S. M., Kirsch, S. H., Hoppstädter, J., Vollmar, A. M., Müller, R., Luzhetskyy, A. N., et al. (2020) · Cancers · doi:10.3390/cancers12051288 · Cited by 39
Sabatino, M. A., Marabese, M., Ganzinelli, M., Caiola, E., Geroni, C., & Broggini, M. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-259 · Cited by 38
Mabuchi, S., Hisamatsu, T., Kawase, C., Hayashi, M., Sawada, K., Mimura, K., Takahashi, K., Takahashi, T., Kurachi, H., & Kimura, T. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2987 · Cited by 37
Molecular mechanisms of action of Trehalose in cancer: A comprehensive review
Chaitanya, N. S. N., Devi, A., Sahu, S., & Alugoju, P. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.118968 · Cited by 37
Takahashi, R., Mabuchi, S., Kawano, M., Sasano, T., Matsumoto, Y., Kuroda, H., Kozasa, K., Hashimoto, K., Sawada, K., & Kimura, T. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151050 · Cited by 37
Massutí, B., Cobo, M., Camps, C., Dómine, M., Provencio, M., Alberola, V., Viñolas, N., Rosell, R., Tarón, M., Gutiérrez, V., et al. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.12.002 · Cited by 31
Rubrolide R: a new furanone metabolite from the ascidianSynoicumof the Indian Ocean
Smitha, D., Muthyala, M. K. K., Hechhu, R., & Rao, D. V. G. L. N. (2013) · Natural Product Research · doi:10.1080/14786419.2013.827194 · Cited by 29
Grosso, F., D’Incalci, M., Cartoafa, M., Nieto, A., Fernández‐Teruel, C., Alfaro, V., Lardelli, P., Roy, E., Gómez, J., Kahatt, C. M., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1864-4 · Cited by 29
Paál, T. A., Liljeblad, A., Kanerva, L. T., Forró, E., & Fülöp, F. (2008) · European Journal of Organic Chemistry · doi:10.1002/ejoc.200800789 · Cited by 29
Forouzesh, B., Hidalgo, M. M., Chu, Q., Mita, A. C., Mita, M. M., Schwartz, G. H., Jimeno, J. M., Gómez, J., Alfaro, V., Lebedinsky, C. A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2889 · Cited by 28
Liu, M.-Y., Zhang, X., & Li, G. (2022) · Chinese Journal of Chemistry · doi:10.1002/cjoc.202200129 · Cited by 28
Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis
Lebedinsky, C. A., Gómez, J., Park, Y. C., Nieto, A., Soto-Matos, A., Parekh, T. V., Alfaro, V., Roy, E., Lardelli, P., & Kahatt, C. M. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1614-z · Cited by 27
New emerging drugs targeting the genomic integrity and replication machinery in ovarian cancer
Brüning, A., & Mylonas, I. G. (2010) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-010-1757-x · Cited by 26
The Role of Trabectedin in Soft Tissue Sarcoma
Nakamura, T., & Sudo, A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.777872 · Cited by 26
Trabectedin in Cancers: Mechanisms and Clinical Applications
Wang, J., Wang, P., Zeng, Z., Lin, C., Lin, Y., Cao, D., Ma, W., Xu, W., Xiang, Q., Luo, L., et al. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220526125806 · Cited by 25
Chu, Q., Mita, A. C., Forouzesh, B., Tolcher, A. W., Schwartz, G. K., Nieto, A., Soto-Matos, A., Alfaro, V., Lebedinsky, C. A., & Rowinsky, E. K. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0062 · Cited by 24
Vermeir, M., Hemeryck, A., Cuyckens, F., Francesch, A., Bockx, M., Houdt, J. V., Steemans, K., Mannens, G., Avilés, P., & Coster, R. D. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.02.020 · Cited by 23
Chuang, Y.-T., & Chang, C. (2012) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2012.07.003 · Cited by 22
Hegde, S. G., & Schmidt, M. A. (2008) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)00025-0 · Cited by 21
Current Approach to Pediatric Soft Tissue Sarcomas
Merchant, M. S., & Mackall, C. L. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0160 · Cited by 21
Santaniello, G., Nebbioso, A., Altucci, L., & Conte, M. (2022) · Marine Drugs · doi:10.3390/md21010024 · Cited by 20
Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines
Duan, Z., Choy, E., Jimeno, J. M., Cuevas, C., Mankin, H. J., & Hornicek, F. J. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0843-2 · Cited by 20
Mori, S., Williams, H. H., Cagle, D., Karanovich, K., Horgen, F. D., Smith, R., & Watanabe, C. M. H. (2015) · Marine Drugs · doi:10.3390/md13106274 · Cited by 19
Colado, E., Paíno, T., Maiso, P., Ocio, E. M., Chen, X., Álvarez-Fernández, S., Gutierrez, N. C., Martín, J., Flores-Montero, J. A., San‐Segundo, L., et al. (2011) · Haematologica · doi:10.3324/haematol.2010.036400 · Cited by 17
Trabectedin for Metastatic Soft Tissue Sarcoma: A Retrospective Single Center Analysis
Schmitt, T., Keller, E. C., Dietrich, S., Wuchter, P., Ho, A. D., & Egerer, G. (2010) · Marine Drugs · doi:10.3390/md8102647 · Cited by 17
Rashid, R. S. M., Temurlu, S., Abourajab, A., Karsili, P., Dinleyici, M., Al-Khateeb, B., & Icil, H. (2023) · Pharmaceuticals · doi:10.3390/ph16040555 · Cited by 16
Zovko, A., Viktorsson, K., Hååg, P., Kovalerchick, D., Färnegårdh, K., Alimonti, A., Ilan, M., Carmeli, S., & Lewensohn, R. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0329 · Cited by 16
Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice
Beumer, J. H., Franke, N. E., Tolboom, R., Buckle, T., Rosing, H., Lázaro, L. L., Schellens, J. H. M., Beijnen, J. H., & van Tellingen, O. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9234-8 · Cited by 14
The value of trabectedin in the treatment of soft tissue sarcoma
Nakamura, T., Matsumine, A., & Sudo, A. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s84789 · Cited by 14
Valero, T., del Barrio, L., Egea, J., Cañas, N., Martı́nez, A., Garcı́a, A. G., Villarroya, M., & López, M. G. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.02.021 · Cited by 13
MAGNUS, P. D., & Matthews, K. S. (2012) · Tetrahedron · doi:10.1016/j.tet.2012.02.043 · Cited by 12
Forró, E., Megyesi, R., Paál, T. A., & Fülöp, F. (2016) · Tetrahedron Asymmetry · doi:10.1016/j.tetasy.2016.10.011 · Cited by 12
Spitzer, G. M., Wellenzohn, B., Markt, P., Kirchmair, J., Langer, T., & Liedl, K. R. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci800455f · Cited by 12
Marine Natural Products — a Vital Source of Novel Biotherapeutics
Begum, S. M. F. M., & Hemalatha, S. (2022) · Current Pharmacology Reports · doi:10.1007/s40495-022-00295-8 · Cited by 11
Navigating the paradox of senescence and chemoresistance in pancreatic cancer
Jeiroshi, A., Deng, J., Xu, Z., Comandatore, A., Xu, G., Glaviano, A., Morelli, L., Garajová, I., & Giovannetti, E. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.06.007 · Cited by 10
Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies
Thertulien, R., Manikhas, G., Dirix, L. Y., Vermorken, J. B., Park, K., Jain, M. M., Jiao, J. J., Natarajan, J., Parekh, T. V., Zannikos, P., et al. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1697-6 · Cited by 9
Pick, A. M., & Nystrom, K. K. (2009) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155209352821 · Cited by 9
Pardo, B., Salazar, R., Ciruelos, E., Cortés-Funes, H., García, M., Majem, M., Montés, A. F., Cuadra, C., Soto-Matos, A., Lebedinsky, C. A., et al. (2011) · Medical Oncology · doi:10.1007/s12032-011-9979-8 · Cited by 8
Recent advances in natural product-based anticancer agents
Negi, A. S., & Jain, S. (2022) · Studies in natural products chemistry · doi:10.1016/b978-0-323-91250-1.00010-0 · Cited by 8
Synthesis and antitumor activity evaluations of albumin-binding prodrugs of CC-1065 analog
Wang, Y., Jiang, J., Jiang, X., Cai, S., Han, H., Li, L., Tian, Z., Jiang, W., Zhang, Z., Xiao, Y., et al. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.05.025 · Cited by 8
Andreeva-Gateva, P. A., & Chakar, S. (2019) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2019.1589449 · Cited by 8
Tsoukalas, N., Tolia, M., Lypas, G., Panopoulos, C. G., Barbounis, V., Koumakis, G., & Efremidis, A. P. (2013) · Oncology Letters · doi:10.3892/ol.2013.1646 · Cited by 7
Anti-cancer agents from natural sources: A review
Nerkar, A. G., Chakraborthy, G. S., & Ukirde, R. D. (2021) · Current Trends in Pharmacy and Pharmaceutical Chemistry · doi:10.18231/j.ctppc.2021.011 · Cited by 7
Naturally occurring, natural product inspired and synthetic heterocyclic anti-cancer drugs
Kaur, M., Kaur, M., Bandopadhyay, T., Sharma, A., Priya, A., Singh, R. A., & Banerjee, B. (2022) · Physical Sciences Reviews · doi:10.1515/psr-2022-0003 · Cited by 6
Zhu, G., Zhao, M., Han, Q., TAN, Y., SUN, Y., Bouvet, M., Singh, S. R., Ye, J., & Hoffman, R. M. (2019) · Anticancer Research · doi:10.21873/anticanres.13805 · Cited by 6
Abid, F. B., Gazzah, A., Ousbane, A., Gutierrez, M., & Brain, E. G. C. (2007) · ONCOLOGIE · doi:10.1007/s10269-007-0785-z · Cited by 5
Marpna, I. D., Shangpliang, O. R., Wanniang, K., Kshiar, B., Lipon, T. M., Laloo, B. M., & Myrboh, B. (2021) · ACS Omega · doi:10.1021/acsomega.1c01466 · Cited by 5
Changes in Neutrophil-to-lymphocyte Ratio Predict Efficacy of Trabectedin for Soft-tissue Sarcoma
Sato, Y., Nakano, K., Kawaguchi, K., Fukuda, N., Wang, X., Urasaki, T., Ohmoto, A., Hayashi, N., Yunokawa, M., Ono, M., et al. (2021) · Cancer Diagnosis & Prognosis · doi:10.21873/cdp.10040 · Cited by 5
Trabectedin combined with liposomal doxorubicin in women with relapsed ovarian cancer
del Campo, J. M., Muñoz‐Couselo, E., de Corcuera, I. D., & Oaknin, A. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.59 · Cited by 5
Chauhan, T., & Shah, M. (2025) · Current Pharmaceutical Analysis · doi:10.1016/j.cpan.2025.01.002 · Cited by 4
Badawy, M. E. I. (2020) · Studies in natural products chemistry · doi:10.1016/b978-0-12-817903-1.00011-5 · Cited by 4
Natural compounds and anticancer effects: The whole is greater than the sum of its parts
Martinotti, S., & Ranzato, E. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816151-7.00003-x · Cited by 4
da Silva, A. G., Rostirola, J. V. C., Speri, F. D., Pina, J. G., Kitahara, M. V., Longato, G. B., & Sciani, J. M. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70165 · Cited by 4
The Importance of Natural Products in Drug Discovery: Opportunities and Success
Nath, R., Nath, R., Mitra, A., Talukdar, A. D., Nath, D., Patra, J. K., Choudhury, M. D., & Kityania, S. (2024) · Interdisciplinary biotechnological advances · doi:10.1007/978-981-97-4600-2_13 · Cited by 3
Treatment with trabectedin: should be indicated to all soft tissue sarcoma histotypes?
Grivas, A., Trafalis, D. T., Thanopoulou, E., Ziras, N., & Athanasiou, A. E. (2010) · PubMed · Cited by 3
Zhu, G., Zhao, M. D., Han, Q., TAN, Y., Sun, Y., Bouvet, M., Clary, B. M., Singh, S. R., Ye, J., & Hoffman, R. M. (2019) · Anticancer Research · doi:10.21873/anticanres.13860 · Cited by 3
Miao, X., Koch, G., Shen, S., Wang, X., Li, J., Shen, X., Qu, J., Straubinger, R. M., & Jusko, W. J. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.10.036 · Cited by 3
Lamm, W. W., Amann, G., & Brodowicz, T. (2010) · Case Reports in Oncology · doi:10.1159/000323261 · Cited by 2
In Vivo and Clinical Studies of Natural Products Targeting the Hallmarks of Cancer
Elbadawi, M., & Efferth, T. (2024) · Handbook of experimental pharmacology · doi:10.1007/164_2024_716 · Cited by 3
Patel, A. S., Wang, D., Sim, H., Ambudkar, S. V., & Chen, Z. (2014) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-09801-2_8 · Cited by 2
P-gp Inhibitory Activity from Marine Sponges, Tunicates and Algae
Huang, X., Kumar, P., Anreddy, N., Xiao, X., Yang, D., & Chen, Z. (2014) · Springer eBooks · doi:10.1007/978-3-319-07145-9_28 · Cited by 2
McKee, T. C., van Wyk, A. W. W., & Whitson, E. L. (2013) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-1-4614-9135-4_3 · Cited by 2
Napoli, M. D., Pepa, C. D., Arenare, L., Scambia, G., Lorusso, D., Raspagliesi, F., Ferrandina, G., Salutari, V., Sorio, R., Mosconi, A. M., et al. (2017) · Supportive Care in Cancer · doi:10.1007/s00520-016-3547-x · Cited by 1
Andrif, M., Elmarrachi, H., & Ismaili, N. (2022) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2022.100677 · Cited by 1
Trabectedin and low-dose radiation therapy in patients with advanced leiomyosarcoma
Martín‐Broto, J., Olarte, A., Fernández, R., Ferreira, M., Carrasco-García, I., Gálvez-Montosa, F., Pérez, I. R., Peinado, J., Azinovic, I., Guzmán-Gómez, L. P., et al. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231225044 · Cited by 1
Bioactive Metabolites Isolated from Microorganisms for Healthcare: Types and Delivery Routes
Mohanta, D., Maneesha, S., Ghangal, R., Solanki, M., & Patnaik, S. (2019) · Environmental chemistry for a sustainable world · doi:10.1007/978-3-030-04675-0_4 · Cited by 1
Cesne, A. L. (2022) · Future Oncology · doi:10.2217/fon-2022-0516 · Cited by 1
Highlights of Natural Products in Prostate Cancer Drug Discovery
Salvador, J. A. R., & Vania, M. (2011) · InTech eBooks · doi:10.5772/27401
Arzneiverordnungen 2007 im Überblick
Schwabe, U. (2008) · Springer eBooks · doi:10.1007/978-3-540-69219-5_1
Management of Ovarian Cancer and Soft Tissue Sarcoma: Focus on Trabectedin
Dahl, K. D. C., Chan, T. W., Balkhi, E., & Zeineldin, R. (2011) · Clinical Medicine Reviews in Oncology · doi:10.4137/cmro.s1605
Exploring the Capabilities of Marine Metabolites
Majumdar, K., Verma, A. K., Kathpalia, K. V., Panja, A. S., & Prabhakar, P. K. (2024) · Advances in medical technologies and clinical practice book series · doi:10.4018/979-8-3693-5878-8.ch005
Metadata
- Authors
- Carter, N. J., & Keam, S. J.
- Affiliations
- Wolters Kluwer Health (NZ)
- Corresponding author
- Carter, Natalie J
- ORCID
- Keam, Susan J
- Venue
- Drugs
- Published
- 2007
- Volume
- 67
- Issue
- 15
- Pages
- 2257-2276
- ISSN
- 0012-6667 (ISSN-L)
- OpenAlex
- W1981744051
- Cited by
- 107
- References
- 57
- Citations by year
- 2025: 3 · 2024: 5 · 2023: 2 · 2022: 11 · 2021: 4 · 2020: 4 · 2019: 5 · 2018: 1 · 2017: 1 · 2016: 5 · 2015: 4 · 2014: 4 · 2013: 3 · 2012: 4
- FWCI
- 10.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Physical Sciences › Chemistry › Organic Chemistry › Synthesis and pharmacology of benzodiazepine derivatives
- Keywords
- trabectedin, Ecteinascidia turbinata, marine natural products, soft tissue sarcoma, ovarian cancer, DNA minor groove binding, nucleotide excision repair, G2/M cell cycle arrest, drug resistance, pharmacokinetics, pharmacodynamics, combination chemotherapy, liposarcoma, leiomyosarcoma, platinum-sensitive ovarian cancer
- MeSH terms
- Trabectedin, Animals, Dioxoles, Female, Humans, Ovarian Neoplasms, Sarcoma, Randomized Controlled Trials as Topic, Antineoplastic Agents, Alkylating, Tetrahydroisoquinolines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
